iSpecimen Inc. Files 8-K for Material Agreement

TL;DR

iSpecimen Inc. signed a new material agreement, filing an 8-K on March 5, 2024.

AI Summary

On March 5, 2024, iSpecimen Inc. filed an 8-K report detailing an entry into a material definitive agreement. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 450 Bedford Street, Suite 1010, Lexington, MA 02420.

Why It Matters

This filing indicates a significant new agreement for iSpecimen Inc., which could impact its business operations and financial performance.

Risk Assessment

Risk Level: medium — The filing of an 8-K for a material definitive agreement suggests a significant event that could carry inherent business risks and opportunities.

Key Players & Entities

• iSpecimen Inc. (company) — Registrant
• March 5, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 450 Bedford Street, Suite 1010, Lexington, MA 02420 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share ISPC The Nasdaq Stock Ma
• $1,500,000 — ng an aggregate offering price of up to $1,500,000 (the "Shares"), from time to time throu

Filing Documents

• tm247835d2_8k.htm (8-K) — 31KB
• tm247835d2_ex5-1.htm (EX-5.1) — 9KB
• tm247835d2_ex10-1.htm (EX-10.1) — 216KB
• tm247835d2_ex5-1img001.jpg (GRAPHIC) — 9KB
• 0001104659-24-030807.txt ( ) — 494KB
• ispc-20240305.xsd (EX-101.SCH) — 3KB
• ispc-20240305_lab.xml (EX-101.LAB) — 33KB
• ispc-20240305_pre.xml (EX-101.PRE) — 22KB
• tm247835d2_8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement. On March 5, 2024, iSpecimen Inc., a Delaware corporation (the "Company"), entered into an At the Market Offering Agreement (the "ATM Agreement") with Rodman & Renshaw LLC as agent (the "Sales Agent") pursuant to which the Company may issue and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $1,500,000 (the "Shares"), from time to time through the Sales Agent (the "Offering"). On March 5, 2024, the Company also filed a prospectus supplement with the Securities and Exchange Commission in connection with the Offering (the "Prospectus Supplement") under its existing Registration Upon delivery of a Sales Notice (as such term is defined in the ATM Agreement) and subject to the terms and conditions of the ATM Agreement, the Sales Agent may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for the Company's common stock. The Company will designate the maximum amount of common stock to be sold through the Sales Agent in any placement under the Offering. Subject to the terms and conditions of the ATM Agreement, the Sales Agent has agreed to use its commercially reasonable efforts to sell on the Company's behalf all of the Shares requested to be sold by the Company. The Company may instruct the Sales Agent not to sell any Shares if the sales cannot be effected at or above a price designated by the Company in a Sales Notice. The Company or the Sales Agent may suspend the offering of the Shares being made through the Sales Agent under the ATM Agreement upon proper notice to the other party. The

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Ellenoff Grossman & Schole LLP 10.1 At the Market Offering Agreement, dated March 5, 2024, between the Company and Rodman & Renshaw LLC 23.1 Consent of Ellenoff Grossman & Schole LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 5, 2024 iSPECIMEN INC. By: /s/ Tracy Curley Name: Tracy Curley Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR